reports
An increasingly favourable environment allows TAKARA BIO to improve to...
The independent financial analyst theScreener just upgraded the general evaluation of TAKARA BIO (JP), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains as moderately risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date February 25, 2022, the closing price was JPY 2,373.00...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.